STK11 mutations are mostly enriched in tumours, expressing high TMB levels with a “cold” tumour immune microenvironment, characterised by reduced density of effector T lymphocytes and increased density of neutrophils [19,43,44]. This evidence concerns the gene STK11 and neoplasm.